SCHEMBL3429944

SCHEMBL3429944

Cn1c(-c2cn3cc(-c4cccc(C(C)(C)O)c4)ccc3n2)nc2ccccc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 5/20 0.62
KCNH2 Q12809 2/20 0.62
ALDH1A3 P47895 7/20 0.44
SLC2A1 P11166 1/20 0.44
ALDH1A1 P00352 6/20 0.41
ALDH1A2 O94788 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
ACSS2 Q9NR19 1/20 0.40
KDM4E B2RXH2 4/20 0.39
TP53 P04637 4/20 0.39
HSD17B10 Q99714 4/20 0.39
NPC1 O15118 3/20 0.39
PKM P14618 3/20 0.39
RAB9A P51151 3/20 0.39
ALOX15 P16050 2/20 0.39
GAA P10253 1/20 0.39
CYP2C9 P11712 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3412505 0.78 NR4A2 (0.64) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL3411468 0.78 NR4A2 (0.67) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL3429756 0.78 NR4A2 (0.69) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL3431737 0.77 NR4A2 (0.75) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL1472110 0.77 NR4A2 (1.00) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL3432175 0.76 NR4A2 (0.67) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL3433850 0.76 NR4A2 (0.66) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL3430915 0.75 NR4A2 (0.68) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL3411598 0.75 NR4A2 (0.65) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1
SCHEMBL219730 0.75 ALDH1A1 (0.42) NR4A2KCNH2ALDH1A3SLC2A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP claimed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US claimed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US claimed
EP-2262805-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2010-12-22 EP claimed
WO-2009144395-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2- Α] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-12-03 WO claimed
EP-2262805-B1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2014-10-22 EP disclosed
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (US) 2013-05-16 US disclosed
US-8338451-B2 Polysubstituted derivatives of 2-heteroaryl-6-phenylimidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI (FR) 2012-12-25 US disclosed
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123288-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1640/4885KCNH2 1938/4885ALDH1A3 1191/4885
US-20110065727-A1 POLYSUBSTITUTED DERIVATIVES OF 2-HETEROARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1640/4885KCNH2 1938/4885ALDH1A3 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.